AC Immune spikes after mid-stage trial data for Parkinson’s drug
LAUSANNE, Switzerland - AC Immune SA revealed promising phase 2 trial results for ACI-7104, an active immunotherapy targeting alpha-synuclein protein aggregates, which contribute to neuron degeneration in Parkinson's disease. In Part 1 of the VacSYn trial, 34 patients received ACI-7104 or a placebo, with all patients generating antibodies against the target antigen following three immunizations.
The treatment was deemed safe and well-tolerated. Antibody penetration into cerebrospinal fluid was observed in all participants, and a signal was noted for total alpha-synuclein reactivity in the fluid, indicating potential target engagement. While Part 1 did not evaluate biomarker or clinical outcomes, exploratory analyses suggested a potential link between antibody levels and disease activity measures.
The trial will extend for two years before advancing to Part 2, designed to provide clinical activity evidence for a phase 3 decision. AC Immune, a clinical-stage biopharmaceutical company, has partnerships valued at over $4.5 billion in potential milestone payments and royalties.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
